Reprogramming of melanoma tumor-infiltrating lymphocytes to induced pluripotent stem cells

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Saito, Hidehito ^a   Okita, Keisuke ^b   Fusaki, Noemi ^c,d   Sabel, Michael S ^a   Chang, Alfred E ^a   Ito, Fumito ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR SOX2;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL REPROGRAMMING TECHNIQUE; CELL STRUCTURE; CONTROLLED STUDY; GENE REARRANGEMENT; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MELANOMA CELL; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENDAI VIRUS; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84956889142     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/8394960     Document Type: Article

References (52)

1. K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, " Cell, vol. 126, no. 4, pp. 663-676, 2006.
2. K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors, " Cell, vol. 131, no. 5, pp. 861-872, 2007.
3. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., "Induced pluripotent stem cell lines derived from human somatic cells, " Science, vol. 318, no. 5858, pp. 1917-1920, 2007.
4. I.-H. Park, R. Zhao, J. A. West et al., "Reprogramming of human somatic cells to pluripotency with defined factors, " Nature, vol. 451, no. 7175, pp. 141-146, 2008.
5. M. E. Brown, E. Rondon, D. Rajesh et al., "Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes, " PLoS ONE, vol. 5, no. 6, Article ID e11373, 2010.
6. Y.-H. Loh, O. Hartung, H. Li et al., "Reprogramming of T cells from human peripheral blood, " Cell Stem Cell, vol. 7, no. 1, pp. 15-19, 2010.
7. T. Seki, S. Yuasa, M. Oda et al., "Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells, " Cell Stem Cell, vol. 7, no. 1, pp. 11-13, 2010.
8. J. Staerk, M. M. Dawlaty, Q. Gao et al., "Reprogramming of human peripheral blood cells to induced pluripotent stemcells, " Cell Stem Cell, vol. 7, no. 1, pp. 20-24, 2010.
9. T. Nishimura, S. Kaneko, A. Kawana-Tachikawa et al., "Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation, " Cell Stem Cell, vol. 12, no. 1, pp. 114-126, 2013.
10. R. Vizcardo, K. Masuda, D. Yamada et al., "Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells, " Cell Stem Cell, vol. 12, no. 1, pp. 31-36, 2013.
11. H. Wakao, K. Yoshikiyo, U. Koshimizu et al., "Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation, " Cell Stem Cell, vol. 12, no. 5, pp. 546-558, 2013.
12. F. Lei, B. Zhao, R. Haque et al., "In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance, " Cancer Research, vol. 71, no. 14, pp. 4742-4747, 2011.
13. M. Themeli, C. C. Kloss, G. Ciriello et al., "Generation of tumortargeted human T lymphocytes from induced pluripotent stem cells for cancer therapy, " Nature Biotechnology, vol. 31, no. 10, pp. 928-933, 2013.
14. T. Inozume, K.-I. Hanada, Q. J. Wang et al., "Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells, " Journal of Immunotherapy, vol. 33, no. 9, pp. 956-964, 2010.
15. M. Ahmadzadeh, L. A. Johnson, B. Heemskerk et al., "Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, " Blood, vol. 114, no. 8, pp. 1537-1544, 2009.
16. L. Baitsch, P. Baumgaertner, E. Devevre et al., "Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients, " Journal of Clinical Investigation, vol. 121, no. 6, pp. 2350-2360, 2011.
17. L. Gattinoni, C. A. Klebanoff, D. C. Palmer et al., "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells, " The Journal of Clinical Investigation, vol. 115, no. 6, pp. 1616-1626, 2005.
18. C. Yee, J. A. Thompson, D. Byrd et al., "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168-16173, 2002.
19. J. Zhou, X. Shen, J. Huang, R. J. Hodes, S. A. Rosenberg, and P. F. Robbins, "Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy, " Journal of Immunology, vol. 175, no. 10, pp. 7046-7052, 2005.
20. M. E. Dudley, C. A. Gross, M. M. Langhan et al., "CD8+ enriched Young tumor infiltrating lymphocytes can mediate regression of metastatic melanoma, " Clinical Cancer Research, vol. 16, no. 24, pp. 6122-6131, 2010.
21. C. Berger, M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott, and S. R. Riddell, "Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates, " Journal of Clinical Investigation, vol. 118, no. 1, pp. 294-305, 2008.
22. C. A. Klebanoff, L. Gattinoni, P. Torabi-Parizi et al., "Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9571-9576, 2005.
23. L. Gattinoni, E. Lugli, Y. Ji et al., "Ahumanmemory T cell subset with stem cell-like properties, " Nature Medicine, vol. 17, no. 10, pp. 1290-1297, 2011.
24. R. Blelloch, Z. Wang, A. Meissner, S. Pollard, A. Smith, and R. Jaenisch, "Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus, " Stem Cells, vol. 24, no. 9, pp. 2007-2013, 2006.
25. S. Eminli, A. Foudi, M. Stadtfeld et al., "Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells, "Nature Genetics, vol. 41, no. 9, pp. 968-976, 2009.
26. M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, "Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients, " Journal of Immunotherapy, vol. 26, no. 4, pp. 332-342, 2003.
27. J. J. M. van Dongen, A. W. Langerak, M. Bruggemann et al., "Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936, " Leukemia, vol. 17, no. 12, pp. 2257-2317, 2003.
28. A. Gros, P. F. Robbins, X. Yao et al., "PD-1 identifies the patientspecific CD8+ tumor-reactive repertoire infiltrating human tumors, "The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2246-2259, 2014.
29. P. Genovese, G. Schiroli, G. Escobar et al., "Targeted genome editing in human repopulating haematopoietic stem cells, " Nature, vol. 510, no. 7504, pp. 235-240, 2014.
30. T. M. Schlaeger, L. Daheron, T. R. Brickler et al., "A comparison of non-integrating reprogramming methods, " Nature Biotechnology, vol. 33, no. 1, pp. 58-63, 2015.
31. S. A. Rosenberg, J. C. Yang, R. M. Sherry et al., "Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, " Clinical Cancer Research, vol. 17, no. 13, pp. 4550-4557, 2011.
32. H. Ban, N. Nishishita, N. Fusaki et al., "Efficient generation of transgene-free human induced pluripotent stemcells (iPSCs) by temperature-sensitive Sendai virus vectors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. 14234-14239, 2011.
33. Y. Fujie, N. Fusaki, T. Katayama et al., "New type of sendai virus vector provides transgene-free iPS cells derived from chimpanzee blood, " PLoS ONE, vol. 9, no. 12, Article IDe113052, 2014.
34. G. Liang, O. Taranova, K. Xia, and Y. Zhang, "Butyratepromotes induced pluripotent stem cell generation, "The Journal of Biological Chemistry, vol. 285, no. 33, pp. 25516-25521, 2010.
35. S. Zhu, W. Li, H. Zhou et al., "Reprogramming of human primary somatic cells by OCT4 and chemical compounds, " Cell Stem Cell, vol. 7, no. 6, pp. 651-655, 2010.
36. D. Huangfu, R. Maehr, W. Guo et al., "Induction of pluripotent stem cells by defined factors is greatly improved by smallmolecule compounds, " Nature Biotechnology, vol. 26, no. 7, pp. 795-797, 2008.
37. W. Li, W. Wei, S. Zhu et al., "Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors, " Cell Stem Cell, vol. 4, no. 1, pp. 16-19, 2009.
38. J. Silva, O. Barrandon, J. Nichols, J. Kawaguchi, T. W. Theunissen, and A. Smith, "Promotion of reprogramming to ground state pluripotency by signal inhibition, " PLoS Biology, vol. 6, no. 10, article e253, 2008.
39. N. Maherali and K. Hochedlinger, "Tgfβ signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc, " Current Biology, vol. 19, no. 20, pp. 1718-1723, 2009.
40. Y. Rais, A. Zviran, S. Geula et al., "Deterministic direct reprogramming of somatic cells to pluripotency, " Nature, vol. 502, no. 7469, pp. 65-70, 2013.
41. C.-W. Chang, Y.-S. Lai, L. S. Lamb Jr., and T. M. Townes, "Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells, " PLoS ONE, vol. 9, no. 5, Article ID e97335, 2014.
42. A. S. Yazdi, K. Morstedt, U. Puchta et al., "Heterogeneity of Tcell clones infiltrating primary malignant melanomas, " Journal of Investigative Dermatology, vol. 126, no. 2, pp. 393-398, 2006.
43. A. M. Menzies, L. E. Haydu, M. S. Carlino et al., "Interand intra-patient heterogeneity of response and progression to targeted therapy inmetastaticmelanoma, " PLoS ONE, vol. 9, no. 1, Article ID e85004, 2014.
44. T. Sjoblom, S. Jones, L. D. Wood et al., "The consensus coding sequences of human breast and colorectal cancers, " Science, vol. 314, no. 5797, pp. 268-274, 2006.
45. M. Gerlinger, A. J. Rowan, S. Horswell et al., "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, "The New England Journal ofMedicine, vol. 366, no. 10, pp. 883-892, 2012.
46. C. G. Mullighan, L. A. Phillips, X. Su et al., "Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia, " Science, vol. 322, no. 5906, pp. 1377-1380, 2008.
47. G. Gallot, S. Vollant, S. Saiagh et al., "T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons froma phase I/II feasibility and safety study, " Journal of Immunotherapy, vol. 37, no. 3, pp. 170-179, 2014.
48. P.-A. Gourraud, L. Gilson, M. Girard, and M. Peschanski, "The role of human leukocyte antigen matching in the development of multiethnic haplobank of induced pluripotent stem cell lines, " Stem Cells, vol. 30, no. 2, pp. 180-186, 2012.
49. A. M. Leen, C. M. Bollard, A. M. Mendizabal et al., "Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation, " Blood, vol. 121, no. 26, pp. 5113-5123, 2013.
50. N. Nakatsuji, F. Nakajima, and K. Tokunaga, "HLA-haplotype banking and iPS cells, " Nature Biotechnology, vol. 26, no. 7, pp. 739-740, 2008.
51. G. N. Stacey, J. M. Crook, D. Hei, and T. Ludwig, "Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells?" Cell Stem Cell, vol. 13, no. 4, pp. 385-388, 2013.
52. M. Turner, S. Leslie, N. G. Martin et al., "Toward the development of a global induced pluripotent stem cell library, " Cell Stem Cell, vol. 13, no. 4, pp. 382-384, 2013.